Volume 1.03 | May 11

Pancreatic Cell News 1.03, May 11, 2010.


TOP STORY

Hypoxia-Inducible Factor-1-Alpha Regulates Beta Cell Function in Mouse and Human Islets
These findings suggest an important role for hypoxia-inducible factor-1-alpha (HIF-1-alpha) in beta cell reserve and regulation of aryl hydrocarbon receptor nuclear translocator expression and demonstrate that HIF-1-alpha is a potential therapeutic target for the beta cell dysfunction of type 2 diabetes. [J Clin Invest]

AggreWellVideo_645x110_v01

SCIENCE NEWS

Pig Pancreas Cells Help Type 1 Diabetics
Pancreatic cells from pigs that have been encapsulated have been successfully transplanted into humans without triggering an immune system attack on the new cells. The transplanted pig pancreas cells quickly began to produce insulin in response to high blood sugar levels in the blood. [Press release from Health Day discussing research to be presented at the 70th Scientific Sessions of the American Diabetes Association]

Popular Diabetes Drug Works Differently Than Thought
The popular diabetes medication metformin works in different fashion than the current widely accepted view. [Press release from University of Cincinnati Metabolic Diseases Institute discussing online prepublication in Cell Metabolism]

Mayo-Led Research Team Develop Agents That Keep Insulin Working Longer
More than half a century after researchers identified a promising way to treat diabetes based on blocking the breakdown of insulin in the body, researchers have developed potent molecules that can do just that. [Press release from Mayo Clinic Florida discussing online prepublication in PLoS One]

Watch Procedure Now  
Further Improve Hematopoietic Progenitor Proliferation
with Human LDL
by STEMCELL Technologies
 
 
ORDER NOW STEMCELL Technologies Inc
 


CURRENT PUBLICATIONS (Ranked by Impact Factor)

DIABETES

Reversal of New-Onset Diabetes Through Modulating Inflammation and Stimulating Beta Cell Replication in Nonobese Diabetic Mice by a Dipeptidyl Peptidase IV Inhibitor
Treatment with NVP-DPP728, a dipeptidyl peptidase IV inhibitor, can reverse new-onset diabetes in nonobese diabetic mice by reducing insulitis, increasing CD4+CD25+FoxP3+ regulatory T cells, and stimulating beta cell replication. [Endocrinology ]

Glial Cell Line-Derived Neurotrophic Factor Enhances Neurogenin3 Gene Expression and Beta Cell Proliferation in the Developing Mouse Pancreas
This data provides evidence of a mechanism by which glial cell line-derived neurotrophic factor (GDNF) influences beta cell development. GDNF could be a potential therapeutic target for the treatment and prevention of diabetes. [Am J Physiol Gastrointest Liver Physiol]

Designed Inhibitors of Insulin-Degrading Enzyme Regulate the Catabolism and Activity of Insulin
Significantly, these results reveal that insulin signaling is normally regulated by insulin-degrading enzyme (IDE) activity not only extracellularly but also within cells, supporting the longstanding view that IDE inhibitors could hold therapeutic value for the treatment of diabetes. [PLoS One]

PANCREATIC CANCER

Involvement of the Tubulin Tyrosine Ligase-Like Family Member 4 Polyglutamylase in PELP1 Polyglutamylation and Chromatin Remodeling in Pancreatic Cancer Cells
Findings imply that tubulin tyrosine ligase-like family member 4 could play important roles in pancreatic carcinogenesis through its polyglutamylase activity and subsequent coordination of chromatin remodeling, and might be a good molecular candidate for the development of new therapeutic strategies for pancreatic cancer. [Cancer Res]

Lkb1 Haploinsufficiency Cooperates with Kras to Promote Pancreatic Cancer via Suppression of p21 Dependent Growth Arrest
Researchers have identified a novel LKB1-p21 axis that suppresses pancreatic ductal adenocarcinoma following Kras mutation in vivo. Downregulation of LKB1 may therefore serve as an alternative to p53 mutation to drive pancreatic cancer in vivo. [Gastroenterology]

CUX1: Target of Akt Signalling and Mediator of Resistance to Apoptosis in Pancreatic Cancer
CUX1 was identified as an important mediator of tumor cell survival in pancreatic cancer in vitro and in vivo. [Gut]

GSK3-Beta and Beta-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer
These data support the hypothesis that glycogen synthase kinase 3-beta (GSK3-beta) modulates the cellular response to radiation in a beta-catenin dependent mechanism. [Neoplasia]

19q13 Amplification is Associated with High Grade and Stage in Pancreatic Cancer
These findings reveal recurrent 19q13 amplification in pancreatic cancer and involvement of the same locus as in bladder, colorectal, ovarian, and thyroid carcinomas. More importantly, the 19q13 amplifications were associated with poor tumor phenotype and showed a trend toward shorter survival. [Genes Chromosomes Cancer]

Cytotherapy with Naive Rat Umbilical Cord Matrix Stem Cells Significantly Attenuates Growth of Murine Pancreatic Cancer Cells and Increases Survival in Syngeneic Mice
The results indicate that naive rat umbilical cord matrix-derived stem cells (UCMSCs) alone remarkably attenuate the growth of pancreatic carcinoma cells in vitro and in a mouse peritoneal model. UCMSC could be a potential tool for targeted cytotherapy for pancreatic cancer. [Cytotherapy]

Dantrolene Mitigates Caerulein-Induced Pancreatitis In Vivo in Mice
The data suggest that the ryanodine receptor (RYR) plays an important role in mediating early acinar cell events during in vivo pancreatitis and contributes to disease severity. Blockade of Ca2+ signals and particularly RYR-Ca2+ may be useful as prophylactic treatment for this disease in high risk settings for pancreatitis. [Am J Physiol Gastrointest Liver Physiol]

Metformin, Independent of AMPK, Inhibits mTORC1 in a Rag GTPase-Dependent Manner
Researchers found that the ability of biguanides to inhibit mTORC1 activation and signaling is dependent on the Rag GTPases. [Cell Metab]

INDUSTRY NEWS

Novocell Becomes ViaCyte, Inc, as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced the Company’s shareholders and Board of Directors approved a name change to ViaCyte, Inc. [ViaCyte, Inc. Press Release]

Cellular Dynamics Partners with iPS Academia Japan, Inc. to In-License Seminal iPS Cell Patent Portfolio
Cellular Dynamics International, Inc. and iPS Academia Japan, Inc. announced a nonexclusive licensing agreement for the seminal induced pluripotent stem cell (iPSC) patent portfolio arising out of the work of Dr. Shinya Yamanaka, M.D, Ph.D., Center for iPS Cell Research and Application, Kyoto University. [Cellular Dynamics International, Inc. Press Release]

Osiris Therapeutics Receives FDA Orphan Drug Designation for Stem Cell Treatment for Type 1 Diabetes
Osiris Therapeutics, Inc. announced that it has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes mellitus. [Osiris Therapeutics, Inc. Press Release]

Oramed Pharmaceuticals Reports Results in Phase IIb Trial of Oral Insulin Administration to Type 2 Diabetes Patients
Oramed Pharmaceuticals Inc. reported results for the recently completed Phase IIb non-FDA clinical trial of its flagship oral insulin capsule, ORMD-0801. [Oramed Pharmaceuticals Inc. Press Release]

Protege Encore Clinical Trial Evaluates New Investigational Approach for Individuals Recently Diagnosed with Type 1 Diabetes
Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. [PR Newswire]

BYDUREON™ FDA Review Timeline Set with PDUFA Action Date of October 22, 2010
Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced that the U.S. Food and Drug Administration (FDA) has classified the BYDUREON™ (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and assigned a new Prescription Drug User Fee Act action date of October 22, 2010. [Amylin Pharmaceuticals, Inc. Press Release]

Diazyme Receives FDA 510(k) Clearance to Market SMART HbA1c Assay on Its SMART Point of Care System for Diabetes Monitoring
Diazyme Laboratories announced that the U.S. Food and Drug Administration (FDA) has granted Diazyme 510(k) clearance to market its SMART HbA1c Assay on its new SMART Point of Care System for diabetes monitoring. [Diazyme Laboratories Press Release]

Biodesign Project Aimed at Earlier Diagnosis of Diabetes
A Biodesign team of researchers has received a new five-year, $3.1 million award from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health. Their goal is to discover and validate telltale molecular signs to learn how to predict who will develop the disease long before any symptoms of diabetes appear. [Biodesign Institute at Arizona State University Press Release]

POLICY NEWS

Senator Introduces the Pancreatic Cancer Research and Education Act (S. 3320)
The Pancreatic Cancer Action Network applauds U.S. Senator Sheldon Whitehouse (D-RI) for the introduction of S. 3320, the Pancreatic Cancer Research and Education Act which focuses on reducing mortality for pancreatic cancer, the fourth leading cause of cancer death in the United States. [United States Congress, United States]

FDA Reviewing Prostate-Cancer Drugs for Heart, Diabetes Risk
The U.S. Food and Drug Administration (FDA) is conducting a safety review of gonadotropin-releasing hormone agonists, which are used to treat prostate cancer. Six studies have indicated that the drugs carry an increased risk of diabetes and/or cardiovascular disease. [Food and Drug Administration, United States]

NSF to Ask Every Grant Applicant for Data Management Plan
Scientists seeking funding from the National Science Foundation (NSF) will soon need to spell out how they plan to manage the data they hope to collect. It’s part of a broader move by NSF and other federal agencies to emphasize the importance of community access to data. [National Science Foundation, United States]

NIH Starts to Flesh out Drug Development Program
Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started-once the program has a budget. [National Institutes of Health, United States]

Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups (NOT-OD-10-089)  [National Institutes of Health, United States]

Drug Safety and Risk Management Advisory Committee; Notice of Meeting [Docket No. FDA-2010-N-0001] [Food and Drug Administration, United States]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes [Docket No. FDA-2010-N-0184] [Food and Drug Administration, United States]

EVENTS

Stem Cells, Tissue Homeostasis and Cancer Conference
May 12-15, 2010
Heidelberg, Germany

Mater Medical Research Institute (MMRI) Stem Cell Symposium 2010: Epigenetics, Transcriptomics and Nanobiotechnology of Stem Cells
May 20-21, 2010
Brisbane, Australia

16th Annual International Society for Cellular Therapy (ISCT) Meeting
May 23-26, 2010
Philadelphia, United States

Systems Biology of Stem Cells
May 24-25, 2010
Irvine, United States

International Scientific Symposium: Stem Cells in Biology and Disease
May 26-28, 2010
Lisbon, Portugal

American Society for Artificial Internal Organs (ASAIO) 56th Annual Conference
May 27-29, 2010
Baltimore, United States

46th American Society of Clinical Oncology (ASCO) Annual Meeting
June 4-8, 2010
Chicago, United States

The First Cedars-Sinai Regenerative Medicine Scientific Symposium
June 14, 2010
Los Angeles, United States


42nd Meeting of the European Pancreatic Club (EPC)
June 16-19, 2010
Stockholm, Sweden


International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States


70th Scientific Sessions of the American Diabetes Association
June 25-29, 2010
Orlando, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom


2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

The European Molecular Biology Organization (EMBO) Meeting – Advancing the Life Sciences
September 4-7, 2010
Barcelona, Spain

The Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS) 2010 Scientific Meeting 
September 9-10, 2010
Oxford, United Kingdom

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States 

Annual Human Proteome Organization (HUPO) World Congress
September 19-23, 2010
Sydney, Australia

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

Fraunhofer Life Science Symposium 2010
October 29-30, 2010
Leipzig, Germany

2010 American Pancreatic Association (APA) Annual Meeting
November 3-6, 2010
Chicago, United States

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES


Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Sr. Product Support and Training Specialist (CardianBCT)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit  here to post your career opportunities.



Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

 
forwardafriendicon

Learn more about Pancreatic Cell News: Archives | Events | Contact Us